

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Susan A. GREENFIELD et al.

Serial No. 09/155,076

Filed October 23, 1998



PEPTIDE FROM SOLUBLE FORM OF
ACETYLCHOLINESTERASE, ACTIVE AS A
CALCIUM CHANNEL MODULATOR

: Group Art Unit 1645

: Examiner S. Turner

RECEIVED

SEP 27 1999

TECH CENTER 1600/2900

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN FEES
FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Attached hereto is a check in the amount of \$55.00 to cover Patent Office fees relating to filing the following attached papers:

Petition for Extension of Time \$55.00

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Susan A. GREENFIELD et al.

By Warren Cheek
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006
Telephone (202) 721-8200
September 21, 1999

[Check No. 34995]
98-0967*


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Susan A. GREENFIELD et al.

Serial No. 09/155,076

Filed October 23, 1998



ATTN: APPLICATION BRANCH
BOX SEQUENCE

PEPTIDE FROM SOLUBLE FORM OF
ACETYLCHOLINESTERASE, ACTIVE AS A
CALCIUM CHANNEL MODULATOR

RESPONSE

Assistant Commissioner for Patents,
Washington, D.C.

Sir:

Responsive to the Notice dated July 21, 1999, there is submitted herewith, in a separate Preliminary Amendment, a paper copy of a Sequence Listing for the above-identified application which has been prepared in accordance with the sequence rules under 37 CFR 1.821-1.825. The Sequence Listing contains the identical sequences appearing in the original application papers. Thus, no new matter has been added.

There is also submitted herewith a copy of the Sequence Listing in computer readable form as required by 37 CFR 1.821(e). The content of the paper and computer readable copies are the same.

A copy of the Notice is also attached as required.

Responsive to the restriction requirement, Applicants elect to prosecute the invention of claims 12-17 and 27-30 (Group I). It is requested that the non-elected claims be permitted to remain dormant in this application until a future date.

*Fenimore
8/26*
In view of the foregoing, it is believed that each requirement set forth in the Notice has

been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Susan A. GREENFIELD et al.

By: Warren Cheek Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C.
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 21, 1999

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7.

Other: _____

Applicant must provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.